In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function

George R. Bousfield1*, Jeffrey V. May1, John S. Davis2,3,4, James A. Dias5 and T. Rajendra Kumar6

1Department of Biological Sciences, Wichita State University, Wichita, KS, United States, 2Department of Obstetrics and Gynecology, University of Nebraska Medical Center, Omaha, NE, United States, 3Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States, 4Nebraska-Western Iowa Health Care System, Omaha, NE, United States, 5Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, United States, 6Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States

Human follicle-stimulating hormone (FSH) exhibits both macro- and microheterogeneity in its carbohydrate moieties. Macroheterogeneity results in three physiologically relevant FSHβ subunit variants, two that possess a single N-linked glycan at either one of the two βL1 loop glycosylation sites or one with both glycans. Microheterogeneity is characterized by 80 to over 100 unique oligosaccharide structures attached to each of the 3 to 4 occupied N-glycosylation sites. With respect to its receptor, partially glycosylated (hypoglycosylated) FSH variants exhibit higher association rates, greater apparent affinity, and greater occupancy than fully glycosylated FSH. Higher receptor binding-activity is reflected by greater in vitro bioactivity and, in some cases, greater in vivo bioactivity. Partially glycosylated pituitary FSH shows an age-related decline in abundance that may be associated with decreased fertility. In this review, we describe an integrated approach involving genetic models, in vitro signaling studies, FSH biochemistry, relevance of physiological changes in FSH glycoform abundance, and characterize the impact of FSH macroheterogeneity on fertility and reproductive aging. We will also address the controversy with regard to claims of a direct action of FSH in mediating bone loss especially at the peri- and postmenopausal stages.

Keywords: pituitary, N-glycosylation, follicle-stimulating hormone, bone, female infertility

STRUCTURAL ATTRIBUTES OF FOLLICLE-STIMULATING HORMONE (FSH) AND ITS SUBUNITS

Follicle-stimulating hormone is one of three gonadotropins in the human glycoprotein hormone family. This hormone family is part of the cystine knot growth factor superfamily, a large group of homo- and heterodimeric signaling molecules (1). FSH plays a central role in reproduction, particularly in females. In the ovary, FSH stimulates follicle development and estrogen synthesis. In the testis, FSH maintains Sertoli cell function, which supports spermatogenesis. Although currently controversial (2, 3), FSH has been claimed to play a direct role in osteoporosis by stimulating differentiation of osteoclasts, which are responsible for removing bone (4). The idea put forth is that in the postmenopausal period when FSH levels rise, activation of osteoclasts results in bone loss. Reports of non-gonadal actions of FSH have recently been summarized (5).
Follicle-stimulating hormone is composed of two dissimilar, cystine knot motif glycoprotein subunits: a common α-subunit and hormone-specific β-subunit (Figure 1) (6). The FSHα subunit amino-acid sequence and disulfide bond organization, including a cystine knot motif, are identical to those in the other glycoprotein hormones, luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and chorionic gonadotropin (CG) (7). However, the N-glycan populations at both glycosylated residues, Asn82 and Asn78, differ from those of the other glycoprotein hormone α-subunits such that these otherwise identical subunits can be distinguished from each other and from free α-subunit by their oligosaccharide populations (8–10). The hormone-specific FSHβ subunit shares 34–40% sequence homology, six conserved disulfide bonds, cystine knot motif, and seatbelt loop with the other human glycoprotein hormone β-subunits (7, 11, 12). While there are two potential N-glycosylation sites in FSHβ, partially glycosylated variants exist that are missing either one of these oligosaccharides (13). These contribute to an unknown degree of charge variation in FSH preparations and result in the classic FSH isoforms (14, 15). The classic interpretation of FSH isoforms was based solely on the notion that variant patterns of negatively charged sialic acid or, to a much lesser extent, sulfate residues terminated oligosaccharide branches, which gave rise to differentially charged isoforms. The observation of hypo-glycosylation further refines our understanding of isoforms, in that net charge may vary, due to presence or absence of entire glycans.

| Follicle-stimulating hormone glycosylation exhibits both macro- and microheterogeneity (Table 1). Macroheterogeneity herein refers to the presence or absence of glycosylation at any one potential glycosylation site. Examples of FSH macroheterogeneity involve the absence of either FSHβ Asn1 or Asn26 oligosaccharides in a population of fully processed and secreted FSH. Microheterogeneity herein refers to as many as 80 to over 100 unique oligosaccharide structures, which can be detected once released from each of the 3–4 glycan-occupied Asn residues in FSH.

Differences in electrophoretic mobility of FSH subunits, revealed by subunit-specific Western blots, provide a convenient means to distinguish four FSH variants resulting from macroheterogeneity. Fully glycosylated hFSHβ migrates as a 24-kDa band (hereinafter, 24k-FSHβ), desN24glycan-FSHβ migrates as a 21-kDa band (21k-FSHβ), and desN′glycan-FSHβ migrates as an 18-kDa band (18k-FSHβ). The FSH heterodimers that incorporate these β-subunit variants are designated, FSH24, FSH21, and FSH18, respectively (19), and are shown in Figure 2. Pituitary extracts also possess a non-glycosylated, 15-kDa FSHβ variant (20). However, the corresponding FSH13 does not appear to be physiologically relevant, because subunit association is extremely inefficient when both FSHβ glycans are missing, and little, if any, FSH heterodimer is secreted (21). FSH24 and FSH21 are detected in FSH derived from human pituitary extracts, as well as from urinary protein preparations (Table 1). When FSH is separated into fully- and hypo-glycosylated fractions, the latter often include FSH14, which can constitute as much as 40% of the hypo-glycosylated FSH preparation (13). As most hFSH21 preparations also possess hFSH18, and are not easily separated, it has become a convention to abbreviate the mixture of physiologically relevant hypo-glycosylated FSH preparations as hFSH21/18.

Follicle-stimulating hormone microheterogeneity results from a structurally heterogeneous population of oligosaccharides attached to each glycosylated Asn residue of the four glycosylation sequons in FSH. Microheterogeneity in this hormone has largely been evaluated at the whole hormone level in studies of pituitary and urinary FSH preparations (16, 22–25). Human pituitary FSH oligosaccharides are 85–98% complex-type, 88–99% are sialylated, 36–46% are biantennary, 30–49% are triantennary, 5–15% are tetra-antennary, while only 4–7% are sulfated (Table 1). The low extent of oligosaccharide sulfation appears to be a human-specific characteristic (no data exist for nonhuman primate FSH glycans), as FSH preparations from cattle, pigs, sheep, and horses possess higher levels of sulfated oligosaccharides, ranging from 13 to 58% (23, 26). Accordingly, a major factor in determining hFSH clearance rates is the extent of sialic acid termination at the non-reducing ends of oligosaccharide branches. As compared with naturally occurring hFSH preparations, recombinant hFSH preparation oligosaccharides exhibit a reduced degree of branching, consisting of largely (55%) biantennary glycans. However, the degree of sialylation in these preparations lags that of urinary hFSH to a lesser extent, because the most abundant urinary FSH triantennary and tetra-antennary glycans are one sialic acid residue short of a full complement (16, 25, 27).

As mentioned above, microheterogeneity contributes to charge variation in FSH, and this has been reported to alter FSH biological activity (14, 28, 29). Comparisons of microheterogeneity in early studies were challenged not only by the large number of oligosaccharide structures encountered, but also by the different
### TABLE 1 | Macro- and microheterogeneity of hFSH preparations.

| FSH preparation | Macrosegregation (% relative abundance) | Microheterogeneity (% relative abundance) |
|-----------------|----------------------------------------|------------------------------------------|
|                 | Pituitary hFSH | Urinary hFSH | Pituitary hFSH<sup>24</sup> | Pituitary hFSH<sup>21</sup> | Pituitary hFSH<sup>18/15</sup> | Recombinant GH<sub>α</sub>-hFSH<sup>24</sup> | Recombinant GH<sub>α</sub>-hFSH<sup>21</sup> |
| FSH<sup>24</sup> | 77            | 86            | 100          | –            | –            | 89            | –            |
| FSH<sup>21</sup> | 23            | 14            | –            | 100          | 60          | 11            | 54          |
| FSH<sup>18</sup> | –            | –            | –            | –            | 40          | –            | 46          |
| FSH<sup>15</sup> | –            | –            | –            | –            | –            | –            | –            |

**Types of oligosaccharides (% relative abundance)**

| Oligosaccharide type | Recombinant GH<sub>α</sub>-hFSH<sup>24</sup> |
|----------------------|-----------------------------------------------|
| Biantennary          | 38.2                                          |
| Triantennary(3)<sup>Δ</sup> | 41.0                                          |
| Triantennary(6)<sup>Δ</sup> | 0.3                                          |
| Tetra-antennary      | 15.0                                          |
| Neutral              | 0.3                                           |
| Sialylated           | 99.1                                          |
| Sulfated             | 6.5                                           |
| Sial/sulfat          | 0.3                                           |
| Core fucose          | 43.0                                          |
| Antenna-fucose       | 0.3                                           |
| Biect GlcNAc         | 32.6                                          |
| GalNAc               | 2.8                                           |

Relative abundance determined by Western blot and mass spectrometry, respectively. Data are limited to those preparations for which both glycoform abundance and glycan microheterogeneity exist.

<sup>Δ</sup> = glycoforms not separated.
<sup>Δ</sup> = third branch attached to Man(α1–3) branch.
<sup>Δ</sup> = third branch attached to Man(α1–6) branch.

Data derived from Ref. (16–18). FSH, follicle-stimulating hormone.

---

**FIGURE 2** | Follicle-stimulating hormone (FSH) glycoform models. Models of FSH heterodimers extracted from pdb 4AY9 decorated with the most abundant glycan observed at each N-glycosylation site by nano-ESI-ion mobility-MS (Bousfield, G. R. and Harvey, D. J., unpublished). Subunits are shown as cartoons rendered by MacPyMOL with subunits and their oligosaccharides colored as in **Figure 1**: FSH<sup>α</sup> green and FSH<sup>β</sup> cyan. Oligosaccharides shown as sticks were created and attached to the FSH model using GLYCAM [Woods Group. (2005–2017) GLYCAM Web. Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA. (http://glycam.org)].

**(A)** FSH<sup>18</sup>, which lacks Asn<sup>15</sup> glycan. **(B)** FSH<sup>21</sup>, which lacks Asn<sup>15</sup> glycan. **(C)** FSH<sup>24</sup>, which possesses all four N-glycans.
analytical methods each group employed, as each of these exhibited bias toward or against specific families of oligosaccharides. We recently characterized microheterogeneity in three purified human pituitary FSH glycoform preparations, as well as highly purified pituitary, urinary, and recombinant hFSH preparations using nano-electrospray mass spectrometry (13, 16–18). Because over 33–109 structures were detected in each sample, comparing oligosaccharide populations derived from different FSH preparations proved challenging.

The oligosaccharide structures shown in Figure 3 represent those present in at least 1% relative abundance in at least FSH preparation. Using this criterion, a total of 54 glycans were selected for comparison. The glycans are organized by position in the N-glycan biosynthetic pathway or by the number of complex branches. Within each antennary group, 2-, 3-, or 4-branch glycans, monosaccharide composition is the basis of organization. Structures 1–7 are oligomannose glycan intermediates found in ER and cisGolgi-derived glycoprotein precursors (Figure 3A). In multi-glycosylation site glycoproteins, these can be found in glycoproteins possessing mature glycans at other sites, when glycan processing at individual sites differs (30). Structures 8 and 9 exhibit the beginnings of complex oligosaccharide synthesis (Figure 3A), structures 10–34 are biantennary glycans (Figures 3A–C), structures 35–48 are triantennary glycans (Figures 3C,D), and structures 49–54 are tetra-antennary glycans (Figure 3D). The oligosaccharide populations of fully glycosylated pituitary FSH (30).

**FIGURE 3 |** Human follicle-stimulating hormone (FSH) oligosaccharide microheterogeneity. Summary of results of nano-ESI mass spectrometry studies showing only those oligosaccharides present at >1% relative abundance in at least one hFSH preparation. The glycan diagram indicates it was detected in the preparation. The Consortium for Functional Glycomics monosaccharide symbols are used in conjunction with Oxford Glycobiology Institute linkage indicators (1–2, —; 1–3, \; 1–4, |; 1–6,/; solid lines indicate β-linkage and dashed lines indicate α-linkage). The bar graphs at the bottom of each panel indicate the relative abundance of the structure in each preparation. The preparations are indicated by single letters as follows: G is GH3-recombinant hFSH; U is urinary hFSH; P is pituitary hFSH; F is fully glycosylated pituitary hFSH\(^{H/2}\); H is hypo-glycosylated pituitary hFSH\(^{H/2}\); and L is hFSH\(^{H/2}\) isolated from hLH preparations. The structures are distributed across four panels beginning with the high mannose precursors and ending with tetra-antennary oligosaccharides, the largest found in hFSH. (A) Structures 1–14. (B) Structures 15–28. (C) Structures 29–42. (D) Structures 43–54.
glycosylated FSH\textsuperscript{14} and hypo-glycosylated FSH\textsuperscript{15} preparations, F and D, respectively, possessed 51 of the 54 major glycans identified in these studies, and 45 of these, representing 88% of these more abundant glycans, were detected in both preparations. Pituitary and urinary FSH preparations P and U, respectively, both possessed 38 glycans (75%) in common with glycoforms F and D, while the hypo-glycosylated hFSH\textsuperscript{3/4} preparation L, possessed 35 glycans (68%) found in glycoform preparations F and D. Recombinant hFSH preparation G, expressed by stably transfected GH\textsubscript{3} cells, displayed the lowest qualitative similarity to FSH\textsuperscript{24} and FSH\textsuperscript{21}, possessing only 28 (55%) of the glycans found in glycoforms F and D. Moreover, the triantennary recombinant hFSH oligosaccharides displayed a different branching pattern.

Raising the cutoff to 4% relative abundance identified four groups of highly abundant glycans. The first group revealed a unique pattern of glycosylation for hFSH\textsuperscript{3/18} preparation L, consisting of a series of high mannose oligosaccharide intermediates possessing 9, 8, 7, 6, 5, and 3 mannose residues (structures 1–7, Figure 3A). Taken in isolation, this observation suggests that these glycoforms may not have exited the biosynthetic pathway. However, complex oligosaccharides, identical to those found in all other FSH preparations examined in this study, were also present in hFSH–L, suggesting oligosaccharide processing occurred at least at one glycosylation site in the Golgi. Glycosylation site-specific glycan analysis, when sufficient samples are available, or top–down proteomics for limited samples, have the potential to demonstrate the presence of both oligomannose and complex glycans in the same hypo-glycosylated hFSH molecule to support this hypothesis. Oligosaccharide structures 2–7 were also found in two pituitary glycoform preparations, hFSH\textsuperscript{14} and hFSH\textsuperscript{15}. However, in both cases, these glycans were present in very low abundance, consistent with their being N-glycan biosynthetic intermediates. Moreover, both secreted hFSH preparations, urinary hFSH and recombinant hFSH, were devoid of oligomannose structures 1–7. In the case of urinary hFSH, this could have resulted either from rapid clearance of oligomannose-containing hFSH from the circulation or bias during purification.

As only secreted recombinant hFSH was recovered from conditioned medium, the absence of oligomannose glycans indicated that mature hFSH secreted by the GH\textsubscript{3} cell line possessed only complex N-glycans. Moreover, the antibody used to capture recombinant hFSH appeared to capture all FSH forms, reducing the likelihood of purification biasing the oligosaccharide population (13). The high abundance of biosynthetic intermediate and low abundance of complex glycans in hFSH\textsuperscript{3/18} preparation L was notable because it exhibited the highest receptor binding-activity of any hFSH preparation we have studied. This led to the concern that we were studying a physiologically irrelevant glycoform. However, subsequent demonstration of significant biological activity differences between other pituitary and recombinant FSH glycoform preparations eliminated this concern (18, 31, 32).

Three clusters of high-abundance, complex glycans were noted in the other five hFSH preparations comprising oligosaccharide structures 22–23, 31–34, and 38–42. Group 2 structure 23, a disialylated, biantennary glycan possessing one GalNAc substituted for Gal, was highly abundant in all five preparations. This was notable, because the absence of sulfated GalNAc from hFSH N-glycans has been attributed to impaired recognition of a Pro-Leu-Arg motif in the common \(\alpha\)-subunit of hFSH by \(\beta\)1, 4-N-acetylgalactosaminyltransferase-T3 and -T4 (GalNAc-T3 and GalNAc-T4, respectively), as compared with hCG and hLH. The resulting reduction in FSH oligosaccharide sulfation was proposed as a consequence of altered motif access in this hormone, probably due to conformational change (33).

Comparison of Pro-Leu-Arg motifs in both hCG crystal structures, 1hc\textsubscript{n} (12) and 1hrp (11), with those in the two hFSH structures found in 1fl7 (6) showed positions of the Pro\textsuperscript{46} and Leu\textsuperscript{41} residue side chains were very similar in all six possible alignments (Figure 4). The Arg\textsuperscript{42} side chains were closely aligned in only one comparison, u-hCG\textsubscript{a2}:r-hFSH\textsubscript{a1} (Figure 4D),
suggesting flexibility in that region of the subunit (6, 34). Indeed, molecular dynamics simulations of FSH bound and unbound to the FSH receptor (FSHR) high-affinity binding site support flexibility in residue 40–47 region as unbound FSH exhibits root mean square fluctuations >1 Å (35). Unbound FSH is the form of the heterodimer recognized by β4GalNAc transferases. When FSH is bound to FSHR, this region loses flexibility, indicating it can achieve a stable conformation when bound to another protein. Thus, pituitary βGalNAc transferases are likely to bind this motif in both hLH and hFSH, consistent with the widespread distribution of GalNAc in hFSH oligosaccharides. The frequent appearance of GalNAc in sulfate-deficient glycans suggests an alternative hypothesis to explain reduced sulfation; human sialyltransferases compete more effectively with sulfotransferase in the human pituitary, leading to preferential addition of Neu5Ac to GalNAc. As N-glycan branches terminated with Neu5Ac-GalNAc were first reported for hLH oligosaccharides, finding this type of GalNAc in hFSH oligosaccharides is well established that FSH carbohydrate is necessary for full FSHRECD model was extracted from pdb 4AY9 and rendered as cartoon using MacPyMOL. The FSH glycoform models are oriented as in Figure 2. The FSHRECD model was extracted from pdb 4AY9 and rendered as cartoon using MacPyMOL. The FSH glycoform models were aligned to the FSH model extracted from the pdb file along with the FSHRECD to illustrate the positions of oligosaccharides relative to the high-affinity binding site in the FSHR. (A) Glycosylated model of FSHα and FSHR extracellular domain. (B) Glycosylated model of FSHβ and FSHR extracellular domain. (C) Glycosylated model of FSHα and FSHR extracellular domain.

31 most likely reflects FSHα subunit glycosylation, while structure 32 reflects FSHβ subunit glycosylation (36, 38). The 4th high abundance glycan cluster, comprising structures 38–42, includes triantennary oligosaccharides possessing only two sialic acid residues. For this group of oligosaccharides, recombinant hFSH differed in the location of the two branch-mannose residues. In pituitary hFSH, GlcNAc transferase IV initiated a third glycan branch on Man (α1–3), while in recombinant hFSH GlcNAc transferase V initiated a third branch on Man (α1–6) (Figure 3C, compare row G with the other five rows). This suggested a difference in the relative activities of GlcNAc transferases IV and V between pituitary gonadotropes and somatotrope-derived GH3 cells, despite the expression of both transferase genes in GH3 cells (18). Another feature of recombinant hFSH glycans was antenna-linked fucose residues, such as observed in structure 43, one of the >1% abundance class of oligosaccharides (18). IMPACT OF FSH GLYOSYLATION HETEROGENEITY ON COGNATE RECEPTOR BINDING

The FSHR is a G-protein-coupled receptor (GPCR) with a leucine-rich repeat extracellular domain comprising 358 amino-acid residues. This ligand binding domain is connected to a 337-residue, hepta-helical transmembrane domain (39, 40). Crystal structures of the high-affinity FSH binding domain in complex with FSH revealed that the interface of the complex involves contacts exclusively via protein–protein interactions (41, 42). FSH oligosaccharides added by modeling do not appear to interact with the extracellular domain engaged with FSH, as they are located on a face of the hormone, which is oriented away from the hormone receptor interface (Figure 5). Since it is well established that FSH carbohydrate is necessary for full FSHR activation (43–46), it seems reasonable to assume that
the carbohydrate affects hormone conformation, which in turn modulates activity. The structure of the entire FSHR (extracellular domain and transmembrane domains) in complex with FSH has yet to be determined, and until then, carbohydrate interaction with the transmembrane domain cannot be ruled out. Alternatively, carbohydrate modulation of FSH conformation may affect the final disposition of FSHR extracellular domain (FSHR_{ECD}) hinge region putative interactions with extracellular loops of the transmembrane domains (34, 47). Consistent with the absence of FSH carbohydrate interaction with FSHR_{ECD}, isolated hybrid-type oligosaccharides related to structure 12 in Figure 3 have no effect on FSHR binding (48). Nevertheless, these oligosaccharides significantly inhibit both basal granulosa cell steroidogenesis, as well as FSH-stimulated steroidogenesis (48). The low affinity of carbohydrate–protein interactions requires sufficiently high oligosaccharide concentrations in inhibition studies that hormone contamination can inhibit binding assays. In our hands, a minimum of two purification steps is necessary to eliminate residual hormone assay interference (48). Accordingly, we attributed hormone contamination in the oligosaccharide preparation as the reason for a report that hCG-derived oligosaccharides inhibited both receptor binding and cellular activation (49).

Loss of a single FSHβ oligosaccharide has three effects on FSH binding to its receptor. First, hypo-glycosylated hFSH immediately engages FSHR preparations, whereas fully glycosylated hFSH24 exhibits about a 30-min lag before FSHR binding begins in earnest (13). Second, hypo-glycosylated hFSH21/18 exhibits a 2.8- to over 14-fold higher apparent affinity for the FSHR as compared with hFSH24 (Table 2). Third, hypo-glycosylated hFSH21/18 occupies 2- to threefold more FSHRs than FSH24 (13, 18). A glance at the structures of FSH glycoforms bound to the FSHR_{ECD} immediately raises the question of how loss of either FSHβ N-glycan facilitates FSH association with the receptor, as neither glycan is close to the binding site (Figure 5). This leaves yet to be defined hindrance by the FSHR transmembrane domain or FSHR oligomerization as potential mechanisms.

The crystal structure of the high-affinity binding site of the FSHR_{ECD} comprised two FSHR domains associated back to back, sandwiched by FSH ligands (41). There was no indication of FSH oligosaccharide interaction with the receptor. The crystal structure of the entire FSHR_{ECD} with FSH bound revealed a strikingly different FSHR_{ECD} conformation as trimeric FSHR–FSH complexes (42). To obtain diffractable crystals in both studies, endoglycosidase-F digestion reduced FSH and FSHR_{ECD} N-glycans to single GlcNAc residues, which eliminated oligosaccharide influence on hormone-receptor binding. The trimeric FSHR crystal structure suggested FSH αAsn52 oligosaccharide, when present, would restrict ligand binding to one glycosylated FSH ligand per FSHR trimer as a biantennary glycan attached to this Asn residue would occupy the center of the trimeric complex (47). While no subsequent studies supporting the dimeric FSHR model have been reported, several lines of evidence appear to support the trimeric FSHR_{ECD} model. Biochemical data in support of the trimeric FSHR model were provided when recombinant-mutant des-αN52-hFSH exhibited threefold greater binding to CHO cells expressing hFSHRs as compared with recombinant wt-hFSH (47). Small molecule allosteric FSHR modulators were reported to increase FSH binding—threefold, suggesting trimeric FSHR complexes dissociating to form FSHR monomers (50–52). Incorporating a transmembrane domain model to the FSHR_{ECD} trimer model predicted that only a single β-arrestin could bind to the trimeric FSHR. Addition of an allosteric modulator to β-arrestin binding assays produced a threefold increase in β-arrestin binding, supporting a model that allosteric small molecule FSHR modulators dissociate FSHR trimers into monomers, thereby increasing FSH access (47). However, a superresolution microscopic technique, dual-color photoactivatable dyes, and localization microscopy (PD-PALM) revealed the closely related LHR existed as a variety of oligomeric forms as well as monomers in the cell membrane (53). Docking of complete LHR models in this study provided a variety of conformations of LHR oligomers, including trimeric LHRs. Similar studies with FSHRs would help clarify the relationship of FSHR.

As greater FSHR occupancy is directly proportional to FSH-stimulated cAMP production by target cells, increased hypo-glycosylated hFSH binding to FSHR is expected to provide a correspondingly greater cellular activation than fully glycosylated hFSH (54). However, since the model of an FSHR trimer can only accommodate one G protein, it is unlikely that the increase in cAMP is due to occupancy alone. Another possibility is that occupancy by hypo-glycosylated FSH fails to engage the GRK/arrestin pathway which would otherwise attenuate the reengagement of G protein subsequent to activation of adenyl cyclase. Another possibility is that hypo-glycosylated FSH creates a more stable complex with FSHR such that during intracellular trafficking, cAMP- and arrestin-mediated persistent signaling (55) is enhanced. Finally, one may also suggest that since the FSH/FSHR complex appears to recycle to the cell surface (56, 57), the high-affinity binding of hypo-glycosylated FSH may have a proclivity for FSHR, thus failing to dissociate upon relocation to the plasma membrane and perhaps reformation of the putative trimeric structures. This could affect the dynamic stoichiometry of the cell surface unoccupied receptor cohort whose ontogeny resets not only with

---

**Table 2** | Follicle-stimulating hormone (FSH) receptor-binding activities of pituitary and recombinant hFSH glycoform preparations.

| FSH preparation | Pituitary hFSH | Urinary hFSH | Pituitary hFSH24 | Pituitary hFSH21/18 | Recombinant GH: hFSH24 | Recombinant GH: hFSH21/18 |
|----------------|----------------|--------------|-----------------|-------------------|---------------------|---------------------|
| FSH RLA potency (IU/mg) | 8,560 | 10,000 | 18,737 | 269,445 | 20,844 | 57,942 |
| FSH21/FSH24 ratio | 14.4 | | | | | 2.8 |

*The radiolabelled tracer was 2.5 ng/tube 125I-hFSH and the receptor preparation was 250,000 FSHR-expressing CHO cells/tube.

Data derived from Ref. (16, 18).*
new FSHR synthesis but also by occupancy/recycling engaged by other members of the orchestra of glycoforms.

**FSHR-MEDIATED SIGNALING IN VITRO AND IN VIVO**

Biased signaling has underpinned GPCR drug development for years but only recently has the mechanism of this phenomenon been revealed in the GPCR field, including the FSHR (51, 58–60). The realization that one GPCR can activate several effector proteins to activate different pathways has prompted the challenging of previously accepted dogma and may help to explain previously unexplained observations. An example of such dogma is that both FSHR and LH/CGR primarily signal via Gαs leading to the activation of the cAMP/protein kinase A (PKA) pathway and subsequently leading to steroidogenesis (51, 61–64). Alternative pathways, such as phospholipase C/inositol triphosphate metabolism were first recognized over 25 years ago (65, 66); however, most studies examining the actions of gonadotropin glycosylation variants remain fixed on the primary pathway. The concept of biased signaling predicts that the specificity of signal transduction depends on, at least in part, the structure of the ligand [reviewed in Ref. (58, 59)]. In support of this idea, a partially deglycosylated eLH variant (67) (eLHdg) was found to exhibit biased signaling through the FSHR (68). While incapable of activating the cAMP/PKA pathway and eliciting steroidogenesis in granulosa cells, binding of eLHdg to FSHR recruited β-arrestins and activated ERK MAPK signaling via a cAMP-independent pathway (68).

Another recent study showed that the oligosaccharide complexity of recombinant hFSH preparations differentially affected gene expression and steroidogenesis in human granulosa cells (69). Our own studies with hFSH glycoforms have found evidence for biased signaling, albeit in different cell types. The hFSH21/18 glycoforms were more active than hFSH24 in activating the cAMP/PKA pathway and phosphorylation of PKA substrates via Gαs in human KGN granulosa cells (31). The actions of FSH21/18 were 10-fold greater than FSH24 on induction of CYP19A1 and estrogen (31). The obvious next step is to determine if this biased signaling by hFSH24 occurs in gonadal cells, which is an active area of pursuit using both in vitro and in vivo genetic approaches.

**GENETIC MODELS TO STUDY THE PHYSIOLOGY OF FSH GLYCOFORMS**

**Fshb Knockout Mice**

As mentioned above, hypo-glycosylated FSH21/18 has been shown to be more avid compared with fully glycosylated FSH24 in several receptor binding assays (13, 18), and more potent when tested using primary granulosa cell- or immortalized granulosa cell-based in vitro assays (31). Translation of these in vitro observations from biochemistry to physiology required the development of new models as well as implementation of existing mouse models. Accordingly, in vivo effects of FSH glycoforms FSH21/18 and FSH24 were evaluated using the experimental design of an in vivo pharmacological rescue approach. In this experimental paradigm, first, immature Fshb null female mice (at 21 days of age) were injected i.p. with different doses of FSH glycoforms separately and at different times postinjection, ovaries were collected for subsequent selected gene expression analysis by quantitative real-time PCR. In these studies, hypo-glycosylated FSH21/18 elicited in vivo bioactivity comparable to that of FSH24; however, these analyses also indicated that differences exist between FSH21/18 and FSH24 glycoforms in inducing a unique subset of FSH-responsive genes (32).

Second, to assess the upstream signaling pathways which control FSH-induced gene expression, immunofluorescence analysis was performed on ovarian sections obtained from Fshb null female mice injected with FSH21/18 and FSH24 glycoforms using p-CREB and p-PKA substrate antibodies. At three different time points tested (0.5, 1, and 2 h), both glycoforms were equally effective and significantly upregulated p-PKA and p-PKA substrates (nuclear accumulation in granulosa cells) over PBS-injected controls, with maximal induction observed at the 1-h time point (32).

In a third set of experiments, ovarian protein extracts were obtained from Fshb null female mice at different time points after injecting with FSH glycoforms separately. These extracts were subjected to Western blot analysis followed by densitometry quantification. When induction of p-CREB, p-PKA substrate and p-p38, p-p44/42, and p-AKT was compared, FSH21/18 hypo-glycosylated FSH, similar to the above assays, was as active as that of FSH24, the fully glycosylated FSH (32). Finally, in ovarian weight gain response assays, FSH21/18 was equally potent as that of the FSH24, although FSH21/18 elicited better estradiol induction compared with that by FSH24 (32). Thus, the in vivo pharmacological rescue experiments suggest biased agonism exhibiting by different FSH glycoforms and, as would be expected, these are nuanced. In addition to determining if this phenomenon occurs in vivo as a function of age (particularly in regard to bone density given the correlation of age with changing FSH glycoform abundance), it will also be critical to determine if these nuances correlate with fertility or embryo quality, having great potential impact on therapeutic use.

In vivo pharmacological rescue of Fshb null male mice was also performed using recombinant human FSH glycoforms and measurement of testicular weight gain between postnatal day 5 and 10 in Fshb null male mice (32). When injected separately into Fshb null male mice at postnatal day 5, both FSH glycoforms significantly induced testicular weight gain by day 10 compared with that in PBS-injected controls (32). Testis weight correlated well with testis tubule size, as well as number of germ cells per tubule. Hypo-glycosylated FSH21/18 was more active than FSH24 (32). Similarly, a subset of FSH-responsive genes in mouse Sertoli cells responded much better to hypo-glycosylated FSH21/18 than fully glycosylated FSH24. Furthermore, the number of BrdU+ Sox9+ proliferating Sertoli cells was also found significantly higher in testes of mice injected with FSH21/18 compared with FSH24 (32).
It is likely that different human FSH glycoforms act via different FSHR-mediated downstream signaling pathways in mouse Sertoli cells, similar to granulosa cells, and elicit distinct gene/protein expression changes. These observations suggest there may be a therapeutic potential advantage of using glycoform-specific hFSH preparations for treatment of male factor fertility, such as marginal sperm counts.

**Evaluation of FSH<sup>15</sup> in Fshb Null Mice**

*In vitro* expression, purification and characterization of recombinant human FSH glycoforms in somatotrope-derived GH<sub>3</sub> cells often results in FSH<sup>21/18</sup> and FSH<sup>24</sup> as the most abundant FSH glycoforms identified by mass spectrometry (18). However, according to the all or none FSHβ glycosylation concept, FSH dimers containing non-glycosylated FSHβ (expected to be 15 kDa in denaturing gels) could also exist in pituitaries (20). To test the biological significance of non-glycosylated FSHβ, separate lines of transgenic mice were first generated that expressed, either a human FSHβ-mutant transgene (HFSHB<sup>Δ23Δ4</sup>) encoding a glycosylation defective 15k-FSHβ subunit or a human FSHB WT transgene (HFSHB<sup>WT</sup>)-encoding wild-type (WT) FSHβ subunit, specifically in gonadotropes. The transgenes were subsequently introduced onto an Fshb null genetic background by intercrossing using a genetic rescue strategy (70).

Real-time qPCR assays, immuno co-localization, and Western blot analyses under denaturing conditions confirmed that the transgene encoded mRNA and the corresponding subunits were abundantly expressed in pituitaries (21). While WT human FSHβ subunit-containing, inter-species hybrid FSH was readily detectable by Western blot analysis under non-denaturing conditions of FHSβ<sup>WT</sup> mouse pituitaries, FSH dimer containing double N-glycosylation-mutant human FSHβ subunit was barely detectable in pituitaries of FHSβ<sup>WT</sup> mice on an Fshb null genetic background (21). Consistent with these expression data, mutant FSHβ subunit-containing FSH dimer was not detectable in either short-term pituitary organ culture media or serum samples by specific RIAs (21). Furthermore, gonad histology, gonad gene expression, and fertility assays all indicated that the double N-glycosylation-mutant HFSβ transgene failed to rescue Fshb null mice (21). Taken together, these genetic experiments confirmed that the double N-glycosylation-mutant human FSHβ subunit-containing FSH dimer is unstable *in vivo*. Such a dimer is also secretion incompetent and even when secreted in low amounts, it fails to rescue mice lacking FSH. Thus, at least one N-glycosylation site on human FSHβ subunit is essential for efficient FSH dimer assembly, secretion, and biological activity *in vivo*.

**SUMMARY OF INTEGRATED RESULTS**

Implementation of Glycoforms in ART/IVF

Fundamental and heretofore unrecognized differences in human FSH relating to the number and location of FSH glycans resulting in FSH glycoforms, FSH<sup>14</sup>, FSH<sup>15</sup>, and FSH<sup>24</sup> (16, 19) have been summarized. Moreover, the seminal observation from analysis of individual human pituitaries was that the abundance of FSH<sup>21</sup> declines with age in women [Table 3 and (16)] raises the question whether this had implications for therapeutic intervention. FSH<sup>21</sup> is elevated in young women of reproductive age, but declines thereafter leading to a condition of FSH<sup>24</sup> dominance. Thus, the active reproductive period is characterized by the presence of FSH<sup>24</sup>, while the period of declining fertility and reproductive senescence is characterized by significantly diminished FSH<sup>21</sup> along with FSH<sup>24</sup> dominance.

In this regard, it is noteworthy that current hFSH products available commercially for clinical use, whether they are of menopausal or recombinant origin, consist overwhelmingly of FSH<sup>24</sup> (18). Thus, despite the general success of IVF, there has not been a systematic clinical trial which considers that a form of the hormone associated physiologically with a period of decreased reproductive function rather than the form of the hormone present during the reproductive period may be compromising both yield and quality of embryos. It is believed that the clinical utilization of hypo-glycosylated FSH<sup>21/24</sup> preparations for IVF would represent a paradigm shift in the treatment of infertility. The use of something truly different, an apparently more active and more physiologically relevant FSH, might provide the basis for improved ovarian stimulation and overall pregnancy outcome. Thus, an emerging question is whether the shift from FSH<sup>21</sup> to FSH<sup>24</sup> dominance occurs as a result of normal aging or a premature change and represents an underlying cause of subfertility/infertility. To place this in context, a brief overview of controlled ovarian stimulation (COS) is warranted.

The use of COS began in the 1980s as a means to enhance/improve the chances of generating a pregnancy via the combination of procedures involved in *in vitro* fertilization (IVF). Prior to this, "natural cycle" IVF was utilized, which generated on average, a single utilisable oocyte (71). Not surprisingly, success via this method was severely limited. COS was developed as a means to generate multiple oocytes, which would increase the chances for successful fertilization, enhance embryo development, and coupled with multiple embryo transfer to the uterus, increase pregnancy rates. Indeed, COS proved invaluable as the preferred mechanism underlying IVF (72, 73). In parallel to COS, increased focus on IVF Laboratory practice coupled with IVF Laboratory Certification greatly moved IVF from "experimental procedure" status to that of standard of care (74). At the core of COS is the utilization of hFSH, the fundamental endocrine driver of ovarian follicle development (72).

The history of COS has witnessed a number of modifications aimed at increasing IVF success. Among these are: the utilization of GnRH agonist or antagonists to block endogenous gonadotropin production; utilization of urinary-derived human menopausal gonadotropin or well-controlled recombinant cDNA-driven expression of hFSH produced primarily using cells

Table 3 includes the relative abundance of FSH<sup>21</sup> in individual human pituitaries.

**TABLE 3** Relative abundance of FSH<sup>21</sup> in individual human pituitaries.

| No. of pituitaries | 2 | 4 | 4 |
|-------------------|---|---|---|
| Age range (years) | 21–24 | 39–43 | 58–71 |
| FSH<sup>21</sup> | 62 ± 10.5 | 41 ± 8.2 | 17 ± 3.7 |

Based on band density in Western blots using anti-FSHβ monoclonal antibody RFSH20 (18).
of Chinese hamster ovary origin; the use of FSH alone or the combined use of FSH coupled with LH; variable gonadotropin dosage and administration regimens; and utilization of supplemental progesterone to offset or oppose estradiol levels (72, 73, 75). Often, modifications have been undertaken to treat women with special conditions that impact success including women with PCOS, older women, and women with cancer (76). Indeed, a women’s age is one of the most predictive factors underlying success with IVF due in large part to the diminishing pool of primordial follicles. The common and overriding feature of the above modifications is the utilization of FSH.

The mechanistic functions and potential differences among FSH glycoforms remain largely unknown. As noted above, differences in receptor binding and the subsequent impact upon certain intracellular signaling systems and cell function can and have been demonstrated (77, 78). The fundamental mechanisms underlying female fertility in terms of producing a viable oocyte still remain largely unknown. However, there are clearly defined stages, which offer targets for differential regulation. These stages include primordial follicle activation, preantral follicle growth, antral follicle growth, and dominant follicle selection. An intriguing hypothesis is that hFSH glycoforms function during different stages of follicle development. This might explain in part, the reported differences in glycoform stimulation of ovarian gene expression and cellular signaling pathways observed in the immature Fshb null mice (32).

Follicle development up to the antral stage is not dependent upon FSH in the mouse (79, 80). Nevertheless, preantral follicles are responsive to FSH (81, 82). Owing to the recently reported in vivo activities of the glycoforms, could FSH21/18 preparations function to drive preantral follicle development to provide follicles appropriately responsive to FSH? Might supplementation with FSH24 for one or two cycles prior to COS overcome what appears to be a natural decline in fertility with age concomitant with a decline in the levels of hFSH21/18? One proposes supplementation in the event that FSH21/18 drives preantral follicle development, so that replacement of FSH by FSH21/18 under standard COS strategies may not provide for improved results if FSH21/18 is needed during the earlier stages of follicle development and ineffective in later stages. Furthermore, such treatment paradigms might serve to ameliorate the decreased responsiveness of older women to COS with commercially available FSH, which is essentially FSH24. There is, for example, some evidence that microheterogeneity differences affect estradiol production (78).

FSH21/18 supplementation over an extended period to promote preantral follicle development, which would serve to provide appropriately developed follicles for continued development, perhaps with either glycoform. Owing to potential differences in uptake and circulating half-life, and whether the glycoforms are under episodic as opposed to a more tonic secretion, differences in hFSH glycoform dose and administration regimen may be needed to provide for a more physiological representation. Clearly, the discovery of FSH21/18 and the initial characterization of its activity provide the basis for new ideas concerning COS and IVF. These data indicate that FSH21/18 and FSH24 exist, and they exhibit differences in both in vitro and in vivo activities, and their relative abundance changes with age. These data provide a compelling basis for continued investigation. Central to the improvement of IVF outcomes will be the understanding of how and when these two glycoforms function to promote the proper developmental program of the follicle.

Implementation of FSH Glycoforms to Preserve Bone

Follicle-stimulating hormone has been reported to have direct effects on bone, attributed to FSH-driven (83–85) osteoclast development and activity (86–89). During the premenopausal period, when ovarian reserve is waning and FSH levels are rising because of the lack of negative feedback by ovarian estrogen (90), the abundance of fully glycosylated hFSH24 in the pituitary also rises. It is well established that declining levels of estradiol during the menopausal transition affects bone mineral density, and other metabolic parameters (91). Since the 1940s it has been assumed that reduced bone mineral density was due to a simple sex steroid deficiency (92). Previous reports, largely from one laboratory, have challenged this view by providing evidence that elevated FSH during menopause or ovarian deficiency might explain the bone loss (86, 93). A number of observations highlight the potential importance of FSH in mediating, at least in part, bone loss in humans (94) not associated with changes in steroid hormones (84). A recent study found that FSH, but not estrogen, was strongly associated with bone loss in postmenopausal women treated for breast cancer (95). Furthermore, polymorphisms in the FSHR are associated with accelerated bone loss in women (96). As such, the levels of estrogen and FSH may contribute in multiple ways to bone mineral density during aging.

It should be appreciated that the extra-gonadal actions of FSH have only been recently identified and the actions of FSH on bone have been controversial [reviewed in Ref. (97)]. Allan et al. (98) reported that FSH produced anabolic effects on bone that correlated with inhibin and testosterone levels. Ritter et al. (99) found that treatment of mice with FSH had no effect on bone loss or gain and did not increase osteoclast formation. Two other groups found little correlation of FSH levels and bone mineral density (2, 100). In contrast, other studies provide evidence that FSH can promote the development of human osteoclast precursor cells (89) and induce the production of bone-resorbing cytokines (87, 88, 93). These are relevant observations since the immune system plays a role in a variety of disease states linking inflammatory responses and bone loss (101). Furthermore, several lines of evidence support the initial observations that loss of either Fshb or Fshr confers protection from bone loss in mice (86).

Geng et al. (102) showed that exogenous FSH enhanced osteoclast differentiation and treatment with neutralizing antibodies to FSH or a GST–FSHβ fusion protein prevented bone loss in ovariec-tomized rats. Likewise, Zhu et al. (103) reported that treatment of ovariec-tomized mice with an FSH antibody prevented bone loss. Our data show that treatment of murine and human osteoclast precursor cells with FSH44, but not FSH24, increases the formation of multi-nucleated, TRAP (tartrate-resistant acid phosphatase-5b, a bone resorption marker) positive osteoclasts (Davis et al., unpublished). FSH also works together with receptor activator of nuclear factor-kB (NFkB) ligand (RANKL) to induce expression of MMP9 and cathepsin-k (CTSK) in osteoclasts. These data are
in agreement with our own and indicate that FSH24 increases TNFa and IRAK mRNA in human CD14+ osteoclast precursors. TNFα is important for osteoclast formation (93, 104, 105). These findings indicate that the age-related increase in hFSH24 may regulate bone, a nontraditional FSH target. Evidence points to the ability of FSH to activate Gα in bone cells, resulting in a reduction in cAMP levels (86), which contrasts to the activation of Gα and increase in cAMP in granulosa cells. In bone, FSH stimulates MAPK and NFκB osteoclastogenic intracellular signaling pathways (86). Our data indicate that FSH24 is responsible for activating these signaling pathways and formation of osteoclasts. Hence, there is a critical need to settle the controversy regarding a role for FSH in targeting osteoclasts in women.

REFERENCES

1. Hearn MTW, Gomme PT. Molecular architecture and biorecognition processes of the cysteine knot protein superfamily: part I. The glycopeptide hormones. J Mol Recognit (2000) 13:223–78. doi:10.1002/1520-0129(200010) 13:5<223::AID-JMR501>3.0.CO;2-L

2. Gao J, Tiwari-Pandey R, Samadfaram R, Yang Y, Miao D, Karapis AC, et al. Altered ovarian function affects skeletal homeostasis independent of the activation of follicle-stimulating hormone. Endocrinology (2007) 148(6):2613–21. doi:10.1210/en.2006-1404

3. Williams GR. Hypogonadal bone loss: sex steroids or gonadotropins? Endocrinology (2007) 148(6):2610–2. doi:10.1210/en.2007-0357

4. Agrawal M, Zhu G, Sun L, Zaidi M, Iqbal J. The role of FSH and TSH in bone loss and its clinical relevance. Curr Osteoporos Rep (2010) 8(4):205–11. doi:10.1007/s11914-010-0028-x

5. Kumar TR. Extragonadal actions of FSH: a critical need for novel genetic models. Endocrinology (2018) 159(1):2–8. doi:10.1210/endo-2017-03118

6. Fox KM, Dias IA, Van Roey P. Three-dimensional structure of human follicle-stimulating hormone. Mol Endocrinol (2001) 15:378–89. doi:10.1210/mend.15.3.0603

7. Bousfield GR, Jia L, Ward DN. Gonadotropins: chemistry and biosynthesis. 3rd ed. In: Neill JD, editor. Knobil and Neill: Physiology of Reproduction. San Diego: Elsevier (2006). p. 1581–634.

8. Maghni-Roger G, Closset J, Hennen G. Differences in the carbohydrate portion of the α subunit of porcine lutropin (LH), follitropin (FSH) and thyrotropin (TSH). FEBS Lett (1975) 60(2):263–6. doi:10.1016/0014-5793 (75)80727-7

9. Nilsson B, Rosen SW, Weintraub BD, Zopf DA. Differences in the carbohydrate moieties of the common α-subunits of human chorionic gonadotropin, lutetinizing hormone, follicle-stimulating hormone, and thyrotropin: preliminary structural inferences from direct methylation analysis. Endocrinology (1986) 119:2737–43. doi:10.1210/endo-119-6-2737

10. Gotschall RR, Bousfield GR. Oligosaccharide mapping reveals hormone-specific glycosylation patterns on equine gonadotropin α-subunit Asn86. Endocrinology (1996) 137(6):543–57. doi:10.1210/endo.137.6.8641208

11. Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, et al. Crystal structure of human chionic gonadotropin. Nature (1994) 369:455–61. doi:10.1038/369455a0

12. Wu H, Lustbader JW, Liu Y, Canfield RE, Hendrickson WA. Structure of human chionic gonadotropin at 2.6 Å resolution from MAD analysis of the selenomethionyl protein. Structure (1994) 2:545–58. doi:10.1016/S0969-2126(00)00054-X

13. Bousfield GR, Butnev VY, Butnev VY, Hiromasa Y, Harvey DJ, May JV. Hypoglycosylated human follicle-stimulating hormone (hFSH21/18) is much more active in vitro than fully-glycosylated hFSH (hFSH24). Mol Endocrinol (2014) 38:989–97. doi:10.1210/mce.2013.11.008

14. Ulhoa-Aguirre A, Midgley AR Jr, Beitsins IZ, Padmanabhan V. Follicle-stimulating isohormones: characterization and physiological relevance. Endocr Rev (1995) 16(6):765–87. doi:10.1210/edrv-16-6-765

AUTHOR CONTRIBUTIONS

GB, JM, JSD, JD, and TK authored individual sections of the review. GB, JM, JD, and TK reviewed the entire manuscript.

FUNDING

This work was supported by the National Institute on Aging (grant number AG029531 to GB, JM, JD, and TK) and The Edgar L. & Patricia M. Makowski Endowment (to TK). This work was supported in part by a Senior Career Scientist Award (to JSD) from the United States (US) Department of Veterans Affairs Biomedical Laboratory Research and Development Service.
31. Bousfield GR, Butnev VY, Butnev VY, Nguyen VT, Gray CM, Westfall S, Davis JS, et al. Evidence for follicle-stimulating hormone receptor as a functional trimer. *J Biol Chem* (2014) 289(20):14273–82. doi:10.1074/jbc.M114.549592
32. Nguyen VT, Singh V, Butnev VY, Gray CM, Westfall S, Davis JS, et al. Inositol phosphate stimulation by LH requires the entire α Asn4 oligosaccharide. *Mol Cell Endocrinol* (2003) 199(1–2):73–86. doi:10.1016/S0303-7207(02)00297-6
33. Thotakura NR, Weintraub BD, Bahl OP. The role of carbohydrate in human chorionadotropin (hCG) action. Effects of N-linked carbohydrate chains from hCG and other glycoproteins on hormonal activity. *Mol Cell Endocrinol* (1997) 13(3):263–72. doi:10.1016/S0303-7207(90)00217-V
34. Janovick JA, Maya-Nunez G, Ulloa-Aguirre A, Huhtaniemi IT, Dias JA, Verboost PM, et al. Increased plasma membrane expression of follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine. *Mol Cell Endocrinol* (2009) 298(1–2):84–8. doi:10.1016/j.mce.2008.09.015
35. Dias JA, Bonnet B, Weaver BA, Watts J, Kuuzetman K, Thomas RM, et al. A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor. *Mol Cell Endocrinol* (2011) 333(2):143–50. doi:10.1016/j.mce.2010.12.023
36. van Koppen CJ, Verboost PM, van Lagenraat M, Karsents WJ, Zoozen HJ, van Acsterberg TA, et al. Signaling of an allosteric, nanomolar potent, low molecular weight agonist for the follicle-stimulating hormone receptor. *Biochem Pharmacol* (2013) 85(8):1162–70. doi:10.1016/j.bcp.2013.02.001
37. Jonas KC, Fanelli F, Huhtaniemi IT, Hanyaloglu AC. Single molecule analysis of functionally asymmetric G protein-coupled receptor (GPCR) oligomers reveals diverse spatial and structural assemblies. *J Biol Chem* (2015) 290:3875–92. doi:10.1074/jbc.M114.622498
38. Bhaskaran RS, Ascoli M. The post-endocytotic fate of the gonadotropin receptors is an important determinant of the desensitization of gonadotropin responses. *J Mol Endocrinol* (2005) 34(4):447–57. doi:10.1677/jme.1.01745
39. Calebiro D, Nikolaevo V, Gagliani MC, de Filippis T, Dees C, Tacchetti C, et al. Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. *PLoS Biol* (2009) 7(8):e1000172. doi:10.1371/journal.pbio.1000172
40. Krishnamurthy H, Kishi H, Shi M, Galet C, Bhaskaran RS, Hirakawa T, et al. Postendocytic trafficking of the follicle-stimulating hormone (FSH)-FSH receptor complex. *Mol Endocrinol* (2003) 17(11):2162–76. doi:10.1210/me.2003-0118
41. Kluetzman KS, Thomas RM, Nechamen CA, Dias JA. Decreased degradation of internalized follicle-stimulating hormone caused by mutation of aspartic acid 6.30(550) in a protein kinase-CK2 consensus sequence in the third intracellular loop of follicle-stimulating hormone receptor. *Biol Reprod* (2011) 84:1145–63. doi:10.1093/biolreprod.110.087965
42. Landomil F, Gallay N, Jégot G, Tranchant T, Durand G, Bourquard T, et al. Biased signalling in follicle-stimulating hormone action. *Mol Cell Endocrinol* (2014) 382(1):452–9. doi:10.1016/j.mce.2013.09.035
43. Luttrell LM. Minireview: more than just a hammer: ligand ‘bias’ and pharmacutical discovery. *Mol Endocrinol* (2014) 28(3):281–94. doi:10.1210/me.2013-1314
44. Shukla AK. Biasing GPCR signaling from inside. *Sci Signal* (2014) 7:e3. doi:10.1126/scisignal.2005021
45. Means AR, MacDonald E, Soderling TR, Corbin JD. Testicular adenosine 3′:5′-monophosphate-dependent protein kinase. Regulation by follicle-stimulating hormone. *J Biol Chem* (1974) 249(4):1311–8.
46. Marsh JM. The role of cyclic AMP in gonadal steroidogenesis. *Biol Reprod* (1976) 14(1):30–53. doi:10.1093/biolreprod14.1.30
47. Dattatreymurthy B, Figgs LW, Reichert LE Jr. Physical and functional association of follitropin receptors with cholora toxin-sensitive guanine nucleotide-binding protein. *J Biol Chem* (1987) 262(24):11737–45.
48. Vanzucckr-Dunn M, Maietlz ET. FSH signaling pathways in immature granulosa cells that regulate target gene expression: branching out from protein kinase A. *Cell Signal* (2006) 18(9):1351–9. doi:10.1016/j.cellsig.2006.02.011

Bousfield et al.

Carbohydrate-Modulated FSH Function

65. Davis JS, Weakland LL, West LA, Fares RV. Luteinizing hormone stimulates the formation of inositol trisphosphate and cyclic AMP in rat granulosa cells. Biochem J (1986) 238:597–604. doi:10.1042/bj2380597

66. Davis JS, Weakland LL, Fares RV, West LA. Luteinizing hormone increases inositol trisphosphate and cytosolic Ca2+ in isolated bovine luteal cells. J Biol Chem (1987) 262(18):8515–21.

80. Butnev VY, Singh V, Nguyen VT, Bousfield GR. Truncated eLH Chem (1987) 262(18):8515–21. doi:10.1016/j.mce.2012.11.021

81. Loreti N, Fresno C, Barrera D, Andreone L, Albarran SL, Fernandez EA, et al. Partially deglycosylated equine LH preferentially activates beta-arrestin-1 in hormone antagonist. Mol Cell Endocrinol (2013) 366(1):68–80. doi:10.1016/j.mce.2012.11.021

82. Devleta B, Adem B, Senada S. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J Bone Miner Metab (2004) 22(4):360–4. doi:10.1007/s00774-004-0495-1

84. Orvieto R, Thuering B, Sezaid M, Gazanier P, Morel V, Vesselle T, et al. FSH and TSH in the regulation of bone density: the pituitary/immune/bone axis. Women & Health, Waltham, MA: Academic Press (2013). p. 307–20.

85. Jungheim ES, Meyer M, Broughton DE. Best practices for controlled ovarian stimulation in IVF. Semin Reprod Med (2015) 33:77–82. doi:10.1055/s-0035-1546424

86. May JV. Ovarian hyperstimulation: effects on oocyte quality and communciation between physician and embryologist to optimize oocyte quality. In: May JV, editor. Infertility and Reproductive Medicine Clinics of North America: Assisted Reproduction, Laboratory Considerations. Philadelphia, PA: WB Saunders Co (1998):163–79.

87. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast osteostimulation. Proc Natl Acad Sci U S A (2006) 103(40):14925–30. doi:10.1073/pnas.0606805103

88. Colaianni G, Cusciro C, Colucci S. FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis. Clin Dev Immunol (2013) 2013:575936. doi:10.1155/2013/575936

89. Allan CM, Kakalik R, Dunstan CR, McTavish KJ, Zhou H, Handelsman DJ, et al. FSH-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci U S A (2010) 107(52):22690–4. doi:10.1073/pnas.1012141108

90. Rittner V, Thuering B, Said Mezard P, Luu Nguyen NH, Seltinemeyer Y, Junker U, et al. Follicle-stimulating hormone does not impact male bone mass in vivo or human male osteoclasts in vitro. Calcif Tissue Int (2008) 82(5):383–9. doi:10.1007/s00228-008-1934-5

91. Duron RJ, Specker BL, Li C, Hammett-Stabler CA, Renner JB, Rubin JE. Follicle-stimulating hormone is independently associated with lean mass but not BMI in younger postmenopausal women. Bone (2012) 50(1):311–6. doi:10.1016/j.bone.2011.11.001

92. Faienza MF, Ventura A, Marzano E, Cavallo L. Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol (2013) 2013:575936. doi:10.1155/2013/575936

93. Zhui L, Blair H, Cao J, Yuen T, Latif R, Guo L, et al. Blocking antibody to the beta-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci U S A (2012) 109(36):14574–9. doi:10.1073/pnas.1212860109

94. Ralston SH, Russell RG, Gowen M. Estrogen inhibits bone loss in a rat ovariectomy-induced osteoporosis model. Biochem Biophys Res Commun (2013) 434(2):280–6. doi:10.1016/j.bbrc.2012.02.116

95. Colaianni G, Cusciro C, Colucci S. FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis. Clin Dev Immunol (2013) 2013:382698. doi:10.1155/2013/382698

96. Allah KM, Al-Rashed A, Al-Mogheer A, Al-Mogheer H, First J, Spinale A, et al. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res (1990) 5(9):983–8. doi:10.1002/jbmr.5650050912

97. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by
which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 98(24):13960–5. doi:10.1073/pnas.251534698

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Bousfield, May, Davis, Dias and Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.